Original ArticleRole of 18F-FDG PET/CT imaging in cardiac and pericardial masses
Introduction
Cardiac tumors are rare entities with high mortality.1,2 Surgical removal is the treatment option of most cases.3 Complete surgical resection can cure most benign heart lesions4 and is also an important treatment for local cardiac malignancies. Palliative surgery is only recommended to relieve rapidly progressing symptoms, in case of unresectable lesions or presence of metastases.5,6 Hence, proper differentiation among these masses and accurate staging of malignant tumors play a vital role in the treatment option.
The two most commonly used noninvasive diagnostic modalities to evaluate suspicious cardiac masses are echocardiography and magnetic resonance imaging (MRI).7, 8, 9, 10, 11 Transthoracic echocardiography (TTE) is the first diagnostic procedure, with a high sensitivity of 93.3%.12 Cardiac MRI provides further information about morphology, location and extent of the mass. CT is recommended for assessing infiltration into the pericardium or the heart itself13 and detecting calcifications,14 especially for patients with contraindications for MRI. However, it is still difficult to accurately discriminate between malignant and benign tumors. Several reports show that 18F-FDG PET/CT can aid noninvasive preoperative determination of malignancy15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 and may be helpful in detecting metastases of malignant cardiac tumors.28, 29, 30
However, there are limited data available on 18F-FDG PET/CT imaging in cardiac/pericardial masses. The aim of this study was to evaluate the ability of 18F-FDG PET/CT imaging in cardiac/pericardial masses in a relatively large sample size.
Section snippets
Patients
This study was approved by the institutional review board of our hospital and informed consent was waived due to its retrospective nature of the study. We retrospectively identified 59 patients referred for 18F-FDG PET/CT evaluation of newly diagnosed cardiac/pericardial masses from August 2010 to October 2019. All patients were referred to assess metabolism of the cardiac tumors and to screen for extracardiac tumor manifestations. The inclusion criteria were as follows: (1) patients underwent
18F-FDG PET/CT Imaging
18F-FDG PET/CT imaging was obtained by the following two PET/CT devices: Discovery VCT 64 (General Electric, Milwaukee, WI, USA) or uMI510 (United Imaging Healthcare, China). The patients performed a standard oncologic preparation without a high-fat/low-carbohydrate diet or heparin intervention. Patients were instructed to fast for at least 6 h, and their blood glucose levels were less than 150 mg/dL before 18F-FDG injection. Whole-body acquisition from head to proximal femora was started about
Patients’ Characteristics, Histology and Location
Fifty-nine patients (32 men, 27 women; mean age ± SD, 50 ± 13 years) according to the inclusion criteria were retrospectively enrolled in the final analysis. Histology served as ground truth. The histologic distributions and anatomic locations are summarized in Table 1.
Of these patients, 30 (50.8%) had nonmalignant lesions (benign tumors and tumor-like lesions), 23 (39.0%) had primary malignant tumors, and six (10.2%) had secondary malignant tumors. The common histologic types were myxoma
Discussion
There are several important findings in this study. First, we identified echocardiographic and PET/CT characteristics that were predictive of cardiac/pericardial malignancy, and especially PET/CT in a large sample size. Second, we demonstrated that 18F-FDG PET/CT was an effective additional image modality in patients with suspected malignant cardiac mass for further confirmation and to screen for potential metastasis, especially for pericardial masses.
Primary tumors of the heart are extremely
Conclusions
In conclusion, PET/CT was used to further delineate characteristics and metastasis for patients with echocardiography suspected malignancy or in more complicated cases. 18F-FDG PET/CT can improve the diagnostic workup of cardiac/pericardial masses in determining tumor malignancy. 18F-FDG PET/CT characteristics are predictive of malignant cardiac/pericardial neoplasm, including SUVmax, size, location in the pericardium, and pericardial effusion. Futhermore, 18F-FDG PET/CT imaging provides the
Acknowledgments
Supported by: Hongyan Yin was sponsored by a Young Scholar Grant from the National Natural Science Foundation of China (81501500) and Hongcheng Shi was supported by Shanghai Municipal Key Clinical Specialty (shslczdzk03401).
Disclosure
Hongyan Yin, Wujian Mao, Hui Tan, Na Zhu, Quan Wan, Jing Shi, Lin Qiu, Yan Xiu, Rongkui Luo, Haojun Yu, Hongcheng Shi have nothing to declare. The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject
References (39)
- et al.
Cardiac tumours: diagnosis and management
Lancet Oncol
(2005) - et al.
Neoplasia and the heart: Pathological review of effects with clinical and radiological correlation
J Am Coll Cardiol
(2018) - et al.
Use of transesophageal echocardiography and contrast echocardiography in the evaluation of cardiac masses
Int J Cardiol
(2017) - et al.
Value of CMR for the differential diagnosis of cardiac masses
JACC Cardiovasc Imaging
(2014) - et al.
Echocardiographic and pathologic characteristics of primary cardiac tumors: a study of 149 cases
Int J Cardiol
(2002) - et al.
MRI and CT appearances of cardiac tumours in adults
Clin Radiol
(2009) - et al.
PET/CT imaging in a case of cardiac liposarcoma
J Nucl Cardiol
(2008) - et al.
Differentiation of malignant from benign heart and pericardial lesions using positron emission tomography and computed tomography
J Nucl Cardiol
(2011) - et al.
Diagnostic performance of cardiac magnetic resonance imaging and echocardiography in evaluation of cardiac and paracardiac masses
Am J Cardiol
(2016) - et al.
Differential diagnosis of cardiac masses using contrast echocardiographic perfusion imaging
J Am Coll Cardiol
(2004)
Cardiac tumors—diagnosis and surgical treatment
Dtsch Arztebl Int
Therapy insight: malignant primary cardiac tumors
Nat Clin Pract Cardiovasc Med
Complete resection of undifferentiated cardiac sarcoma and reconstruction of the atria and the superior vena cava: case report
J Cardiothorac Surg
Cardiac tumors: Echo assessment
Echo Res Pract
CT and MR imaging of benign primary cardiac neoplasms with echocardiographic correlation
Radiographics
Assessment of cardiac masses: magnetic resonance imaging versus transthoracic echocardiography
Anadolu Kardiyol Derg
Heart tumors: Magnetic resonance imaging and multislice spiral CT
Rofo
Effectiveness of preoperative PET examination of huge angiosarcoma of the heart
Clin Nucl Med
Cited by (5)
Scope of PET imaging in the evaluation of cardiac tumors
2023, Cancer Treatment and Research CommunicationsPractical Guide to Interpreting Cardiac Magnetic Resonance in Patients with Cardiac Masses
2023, Journal of Cardiovascular Development and DiseaseMultimodality imaging of cardiac B-cell lymphoma
2023, Journal of Nuclear CardiologyMetabolic Steal of the Myocardium by Primary Cardiac Lymphoma
2023, Case Reports in Oncology
This article includes a PowerPoint file that should be made available as ESM on SpringerLink. Please include the standard Springer ESM text in the note/footer on the first article page. Below this, include the following text: “The authors of this article have provided a PowerPoint file, available for download at SpringerLink, which summarises the contents of the paper and is free for re-use at meetings and presentations. Search for the article DOI on SpringerLink.com.
The authors have also provided an audio summary of the article, which is available to download as ESM, or to listen to via the JNC/ASNC Podcast.
Hongyan Yin, Wujian Mao, and Hui Tan contributed equally to this paper.